

# Key Figures (IFRS)

MORPHOSYS GROUP (in € million, if not stated otherwise)



	12/31/12	12/31/11	12/31/10	12/31/09	12/31/08	12/31/07	12/31/06	12/31/05	12/31/04
<b>RESULTS<sup>1)</sup></b>									
Revenues	51.9	82.1	87.0	81.0	71.6	62.0	53.0	33.5	22.0
Cost of Goods Sold	0.0	0.0	7.3	6.7	7.1	7.9	8.0	2.5	0.9 <sup>2)</sup>
R&D Expenses	37.7	55.9	46.9	39.0	27.6	22.2	17.5	14.0	11.4 <sup>2)</sup>
S, G&A Expenses	12.1	14.9	23.2	23.9	20.5	24.8	21.4	10.8	7.5 <sup>2)</sup>
Personnel Expenses (Excluding Stock-based Compensation)	24.1	27.7	29.6	26.1	21.5	18.8	18.1	10.8	9.1
Capital Expenditure	1.8	2.9	13.8	3.8	3.8	12.0	4.0	0.7	1.7
Depreciation and Amortization of Tangible Assets	1.7	1.7	2.1	1.6	1.5	1.5	1.5	0.9	0.7
Depreciation and Amortization of Intangible Assets	3.5	3.8	4.0	3.8	4.8	3.7	3.4	2.7	2.0
EBITDA	7.9	15.5	19.2	18.1	21.9	13.3	10.3	8.6	3.2
EBIT	2.5	9.8	13.1	12.8	16.5	8.3	5.4	5.3	0.5
Net Profit/(Loss)	1.9	8.2	9.2	9.0	13.2	11.5	6.0	4.7	0.3
Net Profit/(Loss) from Discontinued Operations	-0.4	0.0	-	-	-	-	-	-	-
<b>BALANCE SHEET<sup>2)</sup></b>									
Total Assets	224.3	228.4 <sup>4)</sup>	209.8 <sup>4)</sup>	206.1	203.3	184.7	127.8	80.1	55.8
Cash, Cash Equivalents and Available-for-sale Financial Assets	135.7 <sup>5)</sup>	134.4	108.4	135.1	137.9	106.9	66.0	53.6	37.2
Intangible Assets	35.0	66.0	69.2	17.4	19.7	22.3	14.8	12.4	12.8
Total Liabilities	22.3	31.3 <sup>4)</sup>	23.9 <sup>4)</sup>	32.2	41.3	39.2	27.8	16.1	16.4
Stockholders' Equity	202.2	197.1	185.9	173.9	162.0	145.5	100.1	64.0	39.4
Equity Ratio (in %)	90%	86%	89%	84%	80%	79%	78%	80%	71%
<b>MORPHOSYS SHARE</b>									
Number of Shares Issued	23,358,228	23,112,167	22,890,252	22,660,557	22,478,787	22,160,259	20,145,966	18,077,589	16,316,556
Earnings/(Loss) per Share, Diluted (in €)	0.08 <sup>6)</sup>	0.36 <sup>6)</sup>	0.40	0.40	0.59	0.53	0.31	0.28	0.02
Dividend (in €)	-	-	-	-	-	-	-	-	-
Share Price (in €)	29.30	17.53	18.53	17.04	18.75	16.10	18.12	13.77	12.70
<b>PERSONNEL DATA<sup>3)</sup></b>									
Total Group Employees (Number)	421	446	464	404	334	295	279	172	132
Germany (Number)	328	352	370	301	236	192	183	145	132
Other Countries (Number)	93	94	94	103	98	103	96	27	-

<sup>1)</sup> Due to the Agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the segment AbD Serotec, for the years 2012 and 2011, revenue, income and expenses in connection with the transaction are shown in the line item 'Profit/(Loss) from Discontinued Operations'. All other line items consist of amounts from continuing operations.

<sup>2)</sup> Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the segment AbD Serotec, for the year 2012, the line item 'Total Assets' includes current and non-current assets in connection with the transaction in the amount of € 40.9 million. The line item 'Total Liabilities' includes for the year 2012 current and non-current liabilities in connection with the transaction in the amount of € 3.7 million.

<sup>3)</sup> The total amount 2012 includes 135 employees from discontinued operations of AbD Serotec.

<sup>4)</sup> In 2011, a deferred tax asset in the amount of € 2.3 million has been offset with a deferred tax liability for better transparency. Both deferred tax asset and deferred tax liability relate to income taxes levied by the same tax authority on the same taxable entity. To provide comparative information, prior year's deferred tax asset and deferred tax liability (€ 2.8 million) - and thus total assets as well as total liabilities and stockholders' equity - have been adjusted accordingly.

<sup>5)</sup> Including an interest-bearing assignable loan in the amount of € 10.0 million and including cash reserves of the discontinued AbD Serotec segment in the amount of € 5.3 million

<sup>6)</sup> Consolidated net profit per share (diluted) including discontinued operations from the AbD Serotec segment

<sup>7)</sup> Excluding stock-based compensation